Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025npj Systems Biology and ApplicationsOpen Access

Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKamrine E. PoelsMEMohamed ElmeliegyJHJennifer Hibma

Discussion

Loading...

Member takes

Overview

Quantitative systems pharmacology modeling reveals optimal dosing for elranatamab in multiple myeloma, indicating potential efficacy improvements.

Key Points

  • Model simulations support 76 mg weekly as the optimal dosing regimen for elranatamab in multiple myeloma therapy.
  • A left shift in the dose-response curve indicates that less frequent dosing may maintain efficacy in virtual responders.
  • The pharmacology model explored variability and uncertainty across biological and pharmacologic factors affecting dosing.
  • Baseline levels of sBCMA significantly influence the dose-response relationship and regimen optimization in treatment.

Cite This Study

Poels et al. (2025) studied this question.

synapsesocial.com/papers/68c239e5b210217d6477dcd5https://doi.org/10.1038/s41540-025-00585-z
View Full Paper
Ask AI
Bookmark
Share